0000950170-23-008942 | 10-K | XBRL Viewer

Commitments and Contingencies	12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	3. Commitments and Contingencies Leases In December 2016, the Company entered into an operating lease for office space in Solana Beach, California. The lease commenced on January 1, 2017, was extended in September 2018, December 2019, December 2020, February 2022, and August 2022 and has an expiration date of October 31, 2023, subject to the landlord’s option to cancel upon 30 days written notice, but not sooner than October 31, 2023. According to ASU No. 2016-02, the Company recognized an operating lease ROU asset and liability based on the present value of the future minimum lease payments over the lease term at the commencement date, using the Company’s assumed incremental borrowing rate, and then amortizes the ROU assets over the lease term. The Company applies a discount rate to the minimum lease payments within the lease agreement to determine the value of right-of-use assets and lease liabilities. Unless the rate implicit in the lease is determinable, ASU No. 2016-02 requires the use of the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term for a similar amount to the lease payments in a similar economic environment. The Company noted that the implicit rate in the lease was not determinable and calculated its incremental borrowing rate primarily based on the Company’s assumed borrowing rate of 10% for the years ended December 31, 2022 and 2021. The short-term lease expense of $112,000 is included in the general and administrative expense for the twelve months ended December 31, 2022. The operating lease expense of $38,000 and $138,000 is included in the general and administrative expense for the year ended December 31, 2022 and 2021, respectively. The cash paid for the operating lease liability was $39,000 and $137,000 for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, the Company has future minimum lease payments under its existing facility lease of approximately $134,000 payable in 2023. The remaining lease term was 0.83 years and .08 years as of December 31, 2022 and 2021, respectively. Legal Proceedings On February 25, 2022, the Company received a letter notifying us that Teva Pharmaceuticals, Inc. (“Teva”) submitted to FDA an abbreviated new drug application ("ANDA") for a generic version of Gimoti (metoclopramide hydrochloride) nasal spray eq. 15 mg base/spray that contains Paragraph IV certifications with respect to two of our patents covering Gimoti, U.S. Patent Nos. 8,334,281, expiration date May 16, 2030; and 11,020,361, expiration date December 22, 2029. These patents are listed in FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, for Gimoti. The certifications allege these patents are invalid or will not be infringed by the manufacture, use or sale of Teva’s metoclopramide hydrochloride nasal spray eq. 15 mg base/spray. In April 2022, the Company initiated litigation in the United States District Court for the District of New Jersey, alleging that Teva infringes the patents covering Gimoti. After we initiated litigation, Teva converted to a Paragraph III certification, which prevents FDA from approving Teva’s ANDA until after the latest expiring patent expires in 2030. Consequently, the litigation against Teva has been dismissed.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

3. Commitments and Contingencies

Leases

In December 2016, the Company entered into an operating lease for office space in Solana Beach, California. The lease commenced on January 1, 2017, was extended in September 2018, December 2019, December 2020, February 2022, and August 2022 and has an expiration date of October 31, 2023, subject to the landlord’s option to cancel upon 30 days written notice, but not sooner than October 31, 2023. According to ASU No. 2016-02, the Company recognized an operating lease ROU asset and liability based on the present value of the future minimum lease payments over the lease term at the commencement date, using the Company’s assumed incremental borrowing rate, and then amortizes the ROU assets over the lease term. The Company applies a discount rate to the minimum lease payments within the lease agreement to determine the value of right-of-use assets and lease liabilities. Unless the rate implicit in the lease is determinable, ASU No. 2016-02 requires the use of the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term for a similar amount to the lease payments in a similar economic environment. The Company noted that the implicit rate in the lease was not determinable and calculated its incremental borrowing rate primarily based on the Company’s assumed borrowing rate of 10% for the years ended December 31, 2022 and 2021.

The short-term lease expense of $112,000 is included in the general and administrative expense for the twelve months ended December 31, 2022. The operating lease expense of $38,000 and $138,000 is included in the general and administrative expense for the year ended December 31, 2022 and 2021, respectively. The cash paid for the operating lease liability was $39,000 and $137,000 for the years ended December 31, 2022 and 2021, respectively.

As of December 31, 2022, the Company has future minimum lease payments under its existing facility lease of approximately $134,000 payable in 2023. The remaining lease term was 0.83 years and .08 years as of December 31, 2022 and 2021, respectively.

Legal Proceedings

On February 25, 2022, the Company received a letter notifying us that Teva Pharmaceuticals, Inc. (“Teva”) submitted to FDA an abbreviated new drug application ("ANDA") for a generic version of Gimoti (metoclopramide hydrochloride) nasal spray eq. 15 mg base/spray that contains Paragraph IV certifications with respect to two of our patents covering Gimoti, U.S. Patent Nos. 8,334,281, expiration date May 16, 2030; and 11,020,361, expiration date December 22, 2029. These patents are listed in FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, for Gimoti. The certifications allege these patents are invalid or will not be infringed by the manufacture, use or sale of Teva’s metoclopramide hydrochloride nasal spray eq. 15 mg base/spray. In April 2022, the Company initiated

litigation in the United States District Court for the District of New Jersey, alleging that Teva infringes the patents covering Gimoti. After we initiated litigation, Teva converted to a Paragraph III certification, which prevents FDA from approving Teva’s ANDA until after the latest expiring patent expires in 2030. Consequently, the litigation against Teva has been dismissed.

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2022	Feb. 28, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	Evoke Pharma, Inc.
Entity Central Index Key	0001403708
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Public Float			$ 10.6
Entity Common Stock, Shares Outstanding		3,343,070
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	EVOK
Security Exchange Name	NASDAQ
Entity File Number	001-36075
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-8447886
Entity Address, Address Line One	420 Stevens Avenue
Entity Address, Address Line Two	Suite 370
Entity Address, City or Town	Solana Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92075
City Area Code	858
Local Phone Number	345-1494
Document Annual Report	true
Document Transition Report	false
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s 2023 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant’s fiscal year ended December 31, 2022.
Auditor Firm ID	243
Auditor Name	BDO USA, LLP
Auditor Location	San Diego, California

Employee Benefit Plan

12 Months Ended

Dec. 31, 2022

Retirement Benefits [Abstract]

Employee Benefit Plan

6. Employee Benefit Plan

The Company has established a defined contribution 401(k) plan (the “Plan”) for all employees who are at least 21 years of age. Employees are eligible to participate in the Plan beginning on the date of employment. Under the terms of the Plan, employees may make voluntary contributions as a percentage of compensation. The Company’s contributions to the Plan are discretionary, and no contributions have been made by the Company to date. For the years ended December 31, 2022 and 2021, the Company adopted Safe Harbor 401(k) provisions. No contributions were required to be made to the accounts of employees for the years ended December 31, 2022 and 2021 in order to maintain the Plan’s compliance with Internal Revenue Service regulations.

Income Taxes

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

8. Income Taxes

The Company accounts for uncertain tax positions in accordance with ASC Topic 740, Income Taxes. The application of income tax law and regulations is inherently complex. Interpretations and guidance surrounding income tax laws and regulations change over time. As such, changes in the Company’s subjective assumptions and judgments can materially affect amounts recognized in its financial statements.

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest and penalties on the balance sheet at December 31, 2022. The Company has an uncertain tax position (“UTP”) of approximately $2.0 million related to California net operating losses at December 31, 2022. The Company is subject to taxation in the United States and state jurisdictions, and the Company’s tax years beginning 2007 to date are subject to examination by taxing authorities.

Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through income tax expense.

A reconciliation of the federal statutory income tax rate and the effective income tax rate is as follows for the years ended December 31, 2022 and 2021:


	December 31,
	2022			2021
	(%)			(%)
Federal statutory rate		21			21
Change in valuation allowance		-			5
State income taxes, net of federal credits		2		—
Removal of net operating losses and other credits		(24	)		(25	)
Impact of state tax rate change		1		—
Stock compensation and other permanent items	—				(1	)
Effective income tax rate	—			—

Pursuant to Internal Revenue Code of 1986 (“IRC”) Sections 382 and 383, annual use of the Company’s net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards. Until this analysis has been completed, the Company has excluded the deferred tax assets for net operating losses of approximately $24.5 million and a research and development credit of approximately $3.6 million generated through December 31, 2022 from its deferred tax asset. When this analysis is finalized, the Company plans to update its unrecognized tax benefits accordingly. The Company does not expect this analysis to be completed within the next twelve months and, as a result, the Company does not expect that the unrecognized tax benefits will change within twelve months of this reporting date. Due to the existence of the valuation allowance, future changes in the Company’s unrecognized tax benefits will not impact the Company’s effective tax rate.

Significant components of the Company’s deferred tax assets at December 31, 2022 and 2021 are as follows:


	December 31,
	2022			2021
Deferred tax assets:
Acquired technology	$	-		$	543,000
Stock compensation expense		1,825,000			1,413,000
Capitalized R&D		125,000			-
Lease liability		29,000			3,000
Accruals and other		136,000			110,000
Total deferred tax assets		2,115,000			2,069,000
Deferred tax liabilities:
Right of use asset		(29,000	)		(3,000	)
Total deferred tax liabilities		(29,000	)		(3,000	)
Less valuation allowance		(2,086,000	)		(2,066,000	)
Net deferred tax assets (liabilities)	$	—		$	—

The deferred tax assets and valuation allowance as of December 31, 2022 increased by $20,000, compared to an increase of $444,000 as of December 31, 2021. The Company carries a full valuation allowance against these deferred tax assets, therefore, the adjustments had no effect on the balance sheets, statements of operations and cash flows for the periods presented.

At December 31, 2022, the Company has federal and California net operating loss carryforwards of approximately $100.0 million and $52.1 million, respectively. The federal and California net operating loss carryforwards begin to expire in 2027 and 2028, respectively, unless previously utilized. The portion of federal net operating losses created after 2017 of approximately $38.2 million do not expire and will carry forward indefinitely. At December 31, 2022, the Company also has federal and California research tax credit carryforwards of approximately $2.4 million and $1.5 million, respectively. The federal research credit carryforwards will begin expiring in 2027 unless previously utilized. The California research credit will carry forward indefinitely. Furthermore, under U.S. tax legislation enacted in December 2017, although the treatment of tax losses generated before December 31, 2017 has generally not changed, tax losses generated in calendar year 2018 and beyond do not expire, but may only offset 80% of the Company’s taxable income. This change may require us to pay federal income taxes in future years despite generating a loss for federal income tax purposes in prior years.

California Assembly Bill 85 (“AB 85”), which intends to close a gap in the budget created by the COVID-19 pandemic, was signed into law on June 29, 2020. AB 85 disallows California net operating losses for any taxable year beginning on or after January 1, 2020 and before January 1, 2023 for any corporation with a net business or modified adjusted gross income of more than $1 million for the taxable year. This bill also limits any business credit to offset a maximum of $5 million of California tax, including the California research credit. Senate Bill 113 (SB 113), signed into law February 9, 2022, removes these limitations for tax year 2022, in effect shortening the longer suspension period for NOL deductions and use of tax credits under SB 85. The Company has a taxable loss for the year ended December 31, 2022, and therefore is not affected by the limitation.

There were no changes to unrecognized tax benefits in 2022 and 2021. As such, the balance of unrecognized tax benefits (excluding interest and penalties) was approximately $2.0 million at December 31, 2022 and 2021. The Company will recognize interest and penalties related to unrecognized tax benefits as income tax expense when incurred. To date, since no benefit has been taken related to the UTP, there has been no interest and penalties recognized.

Due to the full valuation allowance that the Company has on the deferred tax assets, there are no unrecognized tax benefits that would impact the effective tax rate, if recognized.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Commercial Services and Loan Agreements with Eversana - Additional Information (Detail) - USD ($)			12 Months Ended
	Feb. 01, 2022	Jan. 21, 2020	Dec. 31, 2022	Dec. 31, 2021	Jan. 31, 2020
Commercial Services And Loan Agreements [Line Items]
Selling, general and administrative			$ 9,623,599	$ 8,851,129
Eversana Agreement [Member]
Commercial Services And Loan Agreements [Line Items]
Unreimbursed commercialization cost			$ 48,400,000
Agreement term			On February 1, 2022, the Eversana Agreement was amended to extend the term from June 19, 2025 (five years from the date the Food & Drug Administration approved the Gimoti new drug application) to December 31, 2026, unless terminated earlier pursuant to its terms.
Agreement expiration date	Dec. 31, 2026
Selling, general and administrative			$ 2,000,000.0	$ 1,300,000
Eversana Agreement [Member] \| Revolving Credit Facility [Member]
Commercial Services And Loan Agreements [Line Items]
Line of credit		$ 5,000,000
Line of credit facility, Interest rate		10.00%
Borrowings					$ 5,000,000
Eversana Agreement [Member] \| Gimoti [Member] \| Minimum [Member]
Commercial Services And Loan Agreements [Line Items]
Percentage of Product Profits		80.00%

Organization and Basis of Presentation

12 Months Ended

Dec. 31, 2022

Organization And Basis Of Presentation [Abstract]

Organization and Basis of Presentation

1. Organization and Basis of Presentation

Evoke Pharma, Inc. (the “Company”) was incorporated under the laws of the state of Delaware in January 2007. The Company is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastroenterological disorders and disease.

Since its inception, the Company has devoted its efforts to developing its sole product, Gimoti (metoclopramide) nasal spray, the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. On June 19, 2020, the Company received approval from the U.S. Food and Drug Administration (“FDA”) for its 505(b)(2) New Drug Application (“NDA”) for Gimoti. The Company launched U.S. commercial sales of Gimoti in October 2020 through its commercial partner Eversana Life Science Services, LLC (“Eversana”).

The Company’s activities are subject to the significant risks and uncertainties associated with any specialty pharmaceutical company that has launched its first commercial product, including market acceptance of the product and the potential need to obtain additional funding for its operations.

Reclassification of Prior Period Balances

The presentation of offering costs in the statement of cash flow for the year ended December 31, 2021, were reclassified to conform with the statement of cash flow presentation for the year ended December 31, 2022.

Going Concern

The financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and negative cash flows from operations since inception and expects to continue to incur net losses for the foreseeable future until such time, if ever, that it can generate significant revenues from the sale of Gimoti. The Company ended 2022 with approximately $9.8 million in cash and cash equivalents. The Company anticipates that it will continue to incur losses from operations due to commercialization activities, including manufacturing Gimoti, conducting the post-marketing commitment single-dose pharmacokinetics (“PK”) clinical trial of Gimoti to characterize dose proportionality of a lower dose strength of Gimoti, and for other general and administrative costs to support the Company’s operations. As a result, the Company believes that there is substantial doubt about its ability to continue as a going concern for one year after the date these financial statements are issued. The financial statements do not include any adjustments that may result from the outcome of this uncertainty.

The Company’s net losses may fluctuate significantly from quarter to quarter and year to year. The Company anticipates that it will be required to raise additional funds through debt, equity or other forms of financing, such as potential collaboration arrangements, to fund future operations and continue as a going concern.

There can be no assurance that additional financing will be available when needed or on acceptable terms. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, and/or suspend or curtail commercialization activities. Any of these actions could materially harm the Company’s business, results of operations, financial condition and future prospects. There can be no assurance that the Company will be able to successfully commercialize Gimoti. Because the Company’s business is entirely dependent on the success of Gimoti, if the Company is unable to secure additional financing, successfully commercialize Gimoti or identify and execute on strategic alternatives for Gimoti or the Company, the Company will be required to curtail all of its activities and may be required to liquidate, dissolve or otherwise wind down its operations.

Impact of COVID-19

Despite the COVID-19 pandemic, the Company began its commercial sales of Gimoti with Eversana in October 2020. The Company has experienced various disruptions to its sales activities, but have continued efforts to reach physicians and customers. For example, Eversana’s commercialization efforts at the time the Company launched Gimoti were adversely affected by operational restrictions imposed on its sales force from quarantines, travel restrictions and bans, and other governmental restrictions related to COVID-19. As a result of these restrictions, Eversana’s sales force was restricted from conducting in-person interactions with certain physicians and customers and was restricted to conducting Gimoti educational and promotional activities virtually in certain circumstances, which impacted Eversana’s ability to more actively market Gimoti. In recent months, certain physician offices have begun to allow more frequent in-person interactions, which has helped to increase the educational and promotional activities of the sales force. The Company anticipates that it and Eversana will continue to be impacted by the COVID-19 pandemic to some extent.

The COVID-19 pandemic has not significantly disrupted the operations of the Company’s third-party suppliers and manufacturers or delayed the Company’s manufacturing timelines of Gimoti, but may negatively impact the Company’s ability to successfully commercialize Gimoti and generate product sales in the future. Further, the COVID-19 pandemic and related mitigation measures have also had an adverse impact on global economic conditions which could have an adverse effect on the Company’s future business and financial condition, including impairing its ability to raise capital when needed.

In March 2020, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was enacted in response to the COVID-19 pandemic. In April 2020, the Company applied for and was approved for a Small Business Administration (“SBA”) loan under the Paycheck Protection Program, established by the CARES Act. On May 1, 2020, the Company received the loan proceeds of approximately $104,000. In January 2021, the Company received notice that its loan and accrued interest were forgiven by the SBA.

Notice of Delisting and Reverse Stock Split

On December 29, 2021, the Company received a letter from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market.

In accordance with Nasdaq listing rules, the Company was provided an initial period of 180 calendar days, or until June 27, 2022, to regain compliance. The letter stated that Nasdaq will provide written notification that the Company has achieved compliance with its rules if at any time before June 27, 2022 the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. The Nasdaq letter had no immediate effect on the listing or trading of the Company’s common stock and the common stock continued to trade on The Nasdaq Capital Market.

On April 27, 2022, the Company’s stockholders granted the board of directors the authority to effect a reverse stock split of the Company’s outstanding common stock. On May 23, 2022 the Company effected a 1-for-12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All of the Company’s issued and outstanding common stock, warrants to purchase common stock, and options to purchase common stock have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented.

On June 7, 2022, the Company received notice from Nasdaq stating that the closing price of the Company’s common stock had been at $1.00 per share or greater for the prior ten consecutive business days and that the Company had regained compliance with the minimum $1.00 per share requirement.

Organization and Basis of Presentation - Additional Information (Detail) - USD ($)			12 Months Ended
	May 23, 2022	May 01, 2020	Dec. 31, 2022	Jun. 26, 2022	Jun. 07, 2022	Dec. 31, 2021	Dec. 29, 2021
Organization And Basis Of Presentation [Line Items]
Month and year of incorporation			2007-01
Cash and cash equivalents			$ 9,843,699			$ 9,144,710
Common stock, par value			$ 0.0001	$ 1.00	$ 1.00	$ 0.0001
Reverse stock split description	1-for-12 reverse stock split
Minimum [Member]
Organization And Basis Of Presentation [Line Items]
Common stock, par value					$ 1.00		$ 1.00
COVID-19 [Member] \| Paycheck Protection Program [Member]
Organization And Basis Of Presentation [Line Items]
Proceeds from loan		$ 104,000

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	3,343,070	2,721,373
Common stock, shares outstanding	3,343,070	2,721,373

Employee Benefit Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Postemployment Benefits [Abstract]
Eligible age for employees for participating in the plan	21 years
Company's contributions to employee benefit plan	$ 0	$ 0

Preferred Stock, Common Stock and Stockholders' Equity - Warrants - Additional Information (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Sale Of Stock [Line Items]
Warrants to purchase shares of common stock expired	139,972	13,517
Issuance of common stock from warrant exercise	0	0
Warrants outstanding to purchase common stock	0	139,972
Weighted average exercise price of warrants outstanding	$ 34.80

Statements of Stockholders' Equity (Deficit) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]
Stock Issuance Cost		$ 1,304,846
Stock Issuance Cost	$ 148,993	$ 6,421

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Reconciliation of Federal Statutory Income Tax Rate and Effective Income Tax Rate

A reconciliation of the federal statutory income tax rate and the effective income tax rate is as follows for the years ended December 31, 2022 and 2021:


	December 31,
	2022			2021
	(%)			(%)
Federal statutory rate		21			21
Change in valuation allowance		-			5
State income taxes, net of federal credits		2		—
Removal of net operating losses and other credits		(24	)		(25	)
Impact of state tax rate change		1		—
Stock compensation and other permanent items	—				(1	)
Effective income tax rate	—			—

Summary of Significant Components of Deferred Tax Assets

Significant components of the Company’s deferred tax assets at December 31, 2022 and 2021 are as follows:


	December 31,
	2022			2021
Deferred tax assets:
Acquired technology	$	-		$	543,000
Stock compensation expense		1,825,000			1,413,000
Capitalized R&D		125,000			-
Lease liability		29,000			3,000
Accruals and other		136,000			110,000
Total deferred tax assets		2,115,000			2,069,000
Deferred tax liabilities:
Right of use asset		(29,000	)		(3,000	)
Total deferred tax liabilities		(29,000	)		(3,000	)
Less valuation allowance		(2,086,000	)		(2,066,000	)
Net deferred tax assets (liabilities)	$	—		$	—

Income Taxes - Additional Information (Detail) - USD ($)		12 Months Ended
	Jun. 29, 2020	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Accrual on interest and penalties related to income taxes		$ 0
Uncertain tax position		2,000,000.0	$ 2,000,000.0
Removal of net operating losses from deferred tax assets		$ 24,500,000
Cumulative change in ownership for limitation of use of net operating loss and research and development credit carryforwards		50.00%
Period of cumulative change of ownership		3 years
Removal of research and development credit from deferred tax assets		$ 3,600,000
Deferred tax asset, Valuation allowance increase		$ 20,000	444,000
Percentage of taxable income offset by tax losses		80.00%
Changes to unrecognized tax benefits		$ 0	$ 0
Unrecognized tax benefits that would affect company's effective tax rate, if recognized		$ 0
Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Tax years subject to examination by taxing authorities		2007
California [Member]
Operating Loss Carryforwards [Line Items]
Uncertain tax position		$ 2,000,000.0
Net operating loss carry forwards		$ 52,100,000
Expiry date of carry forwards		Dec. 31, 2028
California [Member] \| Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit carry forwards		$ 1,500,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forwards		$ 100,000,000.0
Expiry date of carry forwards		Dec. 31, 2027
Net operating loss carryforwards, not subject to expiration		$ 38,200,000
Federal [Member] \| Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit carry forwards		$ 2,400,000
CALIFORNIA [Member]
Operating Loss Carryforwards [Line Items]
Maximum amount of tax offset per year	$ 5,000,000
Required minimum taxable income	$ 1,000,000

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Operating activities
Net loss	$ (8,224,130)	$ (8,537,952)
Adjustments to reconcile net loss to net cash used in operating activities:
Reserve for obsolete inventory		30,000
Forgiveness of paycheck protection loan and accrued interest		(105,130)
Non-cash lease expense	37,025
Stock-based compensation expense	1,458,709	1,878,954
Change in operating assets and liabilities:
Accounts receivable, net	(329,639)	(271,882)
Prepaid expenses and other assets	(29,208)	157,593
Inventory	(103,843)	20,946
Accounts payable and other current liabilities	60,284	(527,859)
Accrued compensation	71,840	(496,915)
Accrued interest expense	500,000	499,301
Operating lease liabilities	(37,025)
Milestone payable		(5,000,000)
Net cash used in operating activities	(6,595,987)	(12,352,944)
Financing activities
Proceeds from issuance of common stock, net		14,375,000
Payment of common stock offering cost		(1,304,846)
Proceeds from issuance of common stock from ATM, net	7,443,969	319,528
Payment of ATM offering costs	(148,993)	(6,421)
Proceeds from issuance of common stock from stock options exercises		45,454
Net cash provided by financing activities	7,294,976	13,428,715
Net increase in cash and cash equivalents	698,989	1,075,771
Cash and cash equivalents at beginning of period	9,144,710	8,068,939
Cash and cash equivalents at end of period	9,843,699	9,144,710
Non-cash financing activities
Forgiveness of paycheck protection loan and accrued interest		$ 105,130
Operating lease right-of-use asset obtained in exchange for operating lease liabilities	$ 153,671

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net product sales	$ 2,508,645	$ 1,618,076
Operating expenses:
Cost of goods sold	$ 370,394	$ 328,118
Cost, Product and Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Research and development	$ 300,789	$ 590,476
Selling, general and administrative	9,623,599	8,851,129
Total operating expenses	10,294,782	9,769,723
Loss from operations	(7,786,137)	(8,151,647)
Other income (expense):
Forgiveness of paycheck protection loan and accrued interest		105,130
Interest income	62,007	8,615
Interest expense	(500,000)	(500,050)
Total other income (expense)	(437,993)	(386,305)
Net loss	$ (8,224,130)	$ (8,537,952)
Net loss per share of common stock, basic	$ (2.62)	$ (3.18)
Net loss per share of common stock, diluted	$ (2.62)	$ (3.18)
Weighted-average shares used to compute basic net loss per share	3,143,626	2,682,145
Weighted-average shares used to compute diluted net loss per share	3,143,626	2,682,145

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Use of Estimates

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment operating in the United States.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and savings accounts.

Fair Value of Financial Instruments

The carrying amounts of all financial instruments, including accounts receivable and accounts payable and accrued expenses, are considered to be representative of their respective fair values because of the short-term nature of those instruments. The carrying value of other short-term and long-term borrowings approximates fair value because of the relative short maturity of these instruments and the interest rates the Company could currently obtain.

Concentrations of Risk

Financial instruments that potentially subject the Company to significant credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits. The Company has established guidelines designed to maintain safety and liquidity, has not experienced any losses in such accounts and believes the exposure to significant risk to the cash balance is minimal.

The Company relies on contract research organizations (“CROs”) and consultants to assist with ongoing regulatory activities. If the CROs and consultants are unable to continue their support, this could adversely affect the Company’s operations.

In addition, the Company relies on third-party manufacturers for the production of Gimoti. If the third-party manufacturers are unable to continue manufacturing Gimoti, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet any development needs or commercial supply demand for Gimoti, and the development and/or commercialization of Gimoti could be materially and adversely affected.

The Company also relies on a dedicated third-party sales team to sell Gimoti. If such third-party organization is unable to continue serving as a dedicated sales team, the commercialization of Gimoti could be materially and adversely affected.

Accounts Receivable

Accounts receivable are recorded net of allowance for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on existing contractual obligations and historical payment patterns. The allowance for doubtful accounts was zero at December 31, 2022 and December 31, 2021, and no bad debt expense was recorded for the years ended December 31, 2022 and December 31, 2021.

Inventory

The Company does not own or operate manufacturing facilities for the production of Gimoti, nor does it plan to develop its own manufacturing operations in the foreseeable future. The Company depends on third-party contract manufacturers for all of its required raw materials, drug substance and finished product for its commercial manufacturing. The Company has agreements with Cosma S.p.A. to supply metoclopramide for the manufacture of Gimoti, and with Thermo Fisher Scientific Inc., through its subsidiary Patheon UK Limited, for the manufacturing of Gimoti. The Company currently utilizes third-party consultants, which it engages on an as-needed, hourly basis, to manage the manufacturing contractors.

Subsequent to FDA approval, the Company began manufacturing Gimoti for commercialization and began capitalizing inventory at that time. The Company’s inventory consisted of approximately $239,000 and $150,000 of raw materials at December 31, 2022 and December 31, 2021, respectively, and approximately $50,000 and $35,000 of finished goods inventory at December 31, 2022 and December 31, 2021, respectively. Inventories are stated at the lower of cost (first-in first-out basis) or net realizable value. Inventory at December 31, 2021 was written down by $30,000 due to establishing a reserve for obsolescence, and this inventory was subsequently destroyed. The Company’s raw materials inventory is held at its third-party suppliers and its work-in-process and finished goods inventory is held at its manufacturer and at Eversana. The Company records such inventory as consigned inventory.

Revenue Recognition

The Company’s ability to generate revenue and become profitable depends on its ability to successfully commercialize Gimoti, which was launched in the United States in October 2020 through the Company’s commercial partner Eversana. If the Company or Eversana fail to successfully grow and maintain sales of Gimoti, the Company may never generate significant revenues and its results of operations and financial position will be adversely affected.

In accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods in an amount that reflects the consideration the Company expects to receive in exchange for the goods provided. Customer control is determined upon the customer’s physical receipt of the product. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with the customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) it satisfies a performance obligation. At contract inception, the Company assesses the goods promised within each contract and determines those that are performance obligations and assesses whether each promised good is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the customer obtains control of the product.

Product sales are recorded at the transaction price, which may include variable considerations for co-payment assistance to commercially insured patients meeting certain eligibility requirements, as well as to uninsured patients. Co-payment assistance is recorded as an offset to gross revenue at the time revenue from the product sale is recognized based on expected

and actual program participation. Co-pay liabilities are estimated using prescribing data available from customers. The Company's analysis also contemplated application of the constraint in accordance with the guidance, under which it determined a significant reversal of revenue would not occur in a future period. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. Liabilities for co-pay assistance of approximately $66,000 and $44,000 at December 31, 2022 and December 31, 2021, respectively, are classified as accounts payable and accrued expenses in the balance sheets. During the year ended December 31, 2021, approximately $718,000 of Gimoti was sold to a third party for research purposes.

Stock-Based Compensation

Stock-based compensation expense for stock option grants and employee stock purchases under the Company’s Employee Stock Purchase Plan (the “ESPP”) is recorded at the estimated fair value of the award as of the grant date and is recognized as expense on a straight-line basis over the employee’s requisite service period, except awards with a performance condition. Awards with a performance condition commence vesting when the satisfaction of the performance condition is probable. The estimation of stock option and ESPP fair value requires management to make estimates and judgments about, among other things, employee exercise behavior, forfeiture rates and volatility of the Company’s common stock. The judgments directly affect the amount of compensation expense that will be recognized.

The Company grants stock options to purchase common stock to employees and members of the board of directors with exercise prices equal to the Company’s closing market price on the date the stock options are granted. The risk-free interest rate assumption was based on the yield of an applicable rate for U.S. Treasury instruments with maturities similar to those of the expected term of the award being valued. The weighted average expected term of options and employee stock purchases was calculated using the simplified method as prescribed by accounting guidance for stock-based compensation. Expected volatility was calculated based on historical volatility of our common stock. The assumed dividend yield was based on the Company never paying cash dividends and having no expectation of paying cash dividends in the foreseeable future. The Company accounts for forfeitures as the forfeitures occur.

Research and Development Expenses

Research and development costs are expensed as incurred and primarily include compensation and related benefits, stock-based compensation expense, costs paid to third-party contractors for product development activities and drug product materials, and technology acquisition milestones. The Company will expense the clinical, regulatory and manufacturing costs related to the post-marketing commitment to conduct a single dose PK clinical trial of Gimoti to characterize dose proportionality of a lower dose strength of Gimoti, as well as other costs that may occur for any additional clinical trials the Company may pursue to expand the indication of Gimoti.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes. Under ASC 740, deferred tax assets and liabilities reflect the future tax consequences of the differences between the financial reporting and tax basis of assets and liabilities using current enacted tax rates. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized.

The Company’s policy related to accounting for uncertainty in income taxes prescribes a recognition threshold and measurement attributed criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock and common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of warrants to purchase common stock and options to purchase common stock under the Company’s equity incentive plan.

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive for the years ended December 31, 2022 and 2021:


	Year Ended December 31,
	2022		2021
Warrants to purchase common stock		-		139,972
Common stock options		491,851		417,788
Total excluded securities		491,851		557,760

Recent Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board, (“FASB”) issued ASU 2016-13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. This update is effective for annual periods beginning after December 15, 2022, and interim periods within those periods, and early adoption is permitted. The new standard will be effective for the Company on January 1, 2023. Management is in the process of evaluating the impact upon adoption on January 1, 2023. Management does not believe the impact will be material.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options, or Subtopic 470-20 and Derivatives and Hedging—Contracts in Entity’s Own Equity, or Subtopic 815-40: Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share, or EPS, calculation in certain areas. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of this new standard did not have a material impact on the Company's consolidated financial statements.

Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 9,843,699	$ 9,144,710
Accounts receivable, net	624,832	295,193
Prepaid expenses	952,954	923,746
Inventory, net	289,378	185,534
Other current assets	11,551	11,551
Total current assets	11,722,414	10,560,734
Operating lease right-of-use asset	129,074	12,428
Total assets	11,851,488	10,573,162
Current Liabilities:
Accounts payable and accrued expenses	934,312	874,028
Accrued compensation	591,158	519,317
Operating lease liability	129,074	12,428
Total current liabilities	1,654,544	1,405,773
Long-term Liabilities:
Note payable	5,000,000	5,000,000
Accrued interest payable	1,112,295	612,295
Total long-term liabilities	6,112,295	5,612,295
Total liabilities	7,766,839	7,018,068
Commitments and contingencies (Note 3)
Stockholders' equity:
Preferred stock, $0.0001 par value; authorized shares - 5,000,000 at December 31, 2022 and 2021; issued and outstanding shares - 0 at December 31, 2022 and 2021 respectively
Common stock, $0.0001 par value; authorized shares - 50,000,000 at December 31, 2022 and 2021; issued and outstanding shares - 3,343,070 and 2,721,373 at December 31, 2022 and 2021, respectively	334	272
Additional paid-in capital	119,731,458	110,977,835
Accumulated deficit	(115,647,143)	(107,423,013)
Total stockholders' equity	4,084,649	3,555,094
Total liabilities and stockholders' equity	$ 11,851,488	$ 10,573,162

Commitments and Contingencies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Lease commencement date	Jan. 01, 2017
Lessee operating lease existence of option to extend	true
Lease expiry date	Oct. 31, 2023
Operating lease incremental borrowing rate	10.00%	10.00%
Cash paid for the operating lease liability	$ 39,000	$ 137,000
Remaining lease term	9 months 29 days	29 days
Future minimum facility lease payments due in 2022		$ 134,000
General and administrative expense [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Short-term lease expense	$ 112,000
Operating lease expense	38,000	138,000
Rent expense	$ 38,000	$ 138,000

Technology Acquisition Agreement - Additional Information (Detail)	1 Months Ended			12 Months Ended
	Jul. 31, 2021 USD ($)	May 31, 2014 USD ($)	Jun. 30, 2007 USD ($)	Dec. 31, 2022 USD ($) Milestone	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2021 USD ($)
Technology Acquisition Agreement [Line Items]
Payment expensed as in-process research and development			$ 650,000
Milestone payment					$ (5,000,000)
Mallinckrodt Plc [Member]
Technology Acquisition Agreement [Line Items]
Milestone payments contingent amount				$ 5,000,000
Number of milestone payments \| Milestone				1
Mallinckrodt Plc [Member] \| Gimoti [Member]
Technology Acquisition Agreement [Line Items]
Milestone payment	$ 5,000,000
Amount payable to Mallinckro dt							$ 5,000,000
Research and development expense payable						$ 5,000,000
Mallinckrodt Plc [Member] \| Rights and Patents Acquired from Questcor Pharmaceuticals Inc [Member] \| Maximum [Member]
Technology Acquisition Agreement [Line Items]
Milestone payments contingent amount				$ 52,000,000
Development Target One [Member] \| Rights and Patents Acquired from Questcor Pharmaceuticals Inc [Member]
Technology Acquisition Agreement [Line Items]
Milestone payment		$ 500,000
Development targets description				upon the initiation of the first patient dosing in the Company’s Phase 3 clinical trial for Gimoti
Development Target Four [Member] \| Mallinckrodt Plc [Member] \| Patented Technology [Member]
Technology Acquisition Agreement [Line Items]
Development targets description				depended on Gimoti’s commercial success. The Company was required to pay Mallinckrodt a low single digit royalty percentage on net sales of Gimoti
Milestone payments contingent amount				$ 47,000,000
Royalties on net sales				$ 134,000

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share


	Year Ended December 31,
	2022		2021
Warrants to purchase common stock		-		139,972
Common stock options		491,851		417,788
Total excluded securities		491,851		557,760

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2022 USD ($) Segment	Dec. 31, 2021 USD ($)
Significant Accounting Policies [Line Items]
Number of operating segment \| Segment	1
Allowance for doubtful accounts receivable	$ 0	$ 0
Bad debt expense	0	0
Inventory raw materials	239,000	150,000
Inventory finished goods	50,000	35,000
Inventory reserve for obsoletion		30,000
Gimoti [Member]
Significant Accounting Policies [Line Items]
Purchase by third party for research purposes		718,000
Accounts Payable and Accrued Expenses [Member]
Significant Accounting Policies [Line Items]
Liabilities for co-pay assistance	$ 66,000	$ 44,000

Income Taxes - Reconciliation of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal statutory rate	21.00%	21.00%
Change in valuation allowance		5.00%
State income taxes, net of federal credits	2.00%
Removal of net operating losses and other credits	(24.00%)	(25.00%)
Impact of state tax rate change	1.00%
Stock compensation and other permanent items		(1.00%)

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Use of Estimates

Segment Reporting

Cash and Cash Equivalents

Fair Value of Financial Instruments

Concentrations of Risk

Accounts Receivable

Inventory

Revenue Recognition

Stock-Based Compensation

Research and Development Expenses

Income Taxes

Net Loss Per Share


	Year Ended December 31,
	2022		2021
Warrants to purchase common stock		-		139,972
Common stock options		491,851		417,788
Total excluded securities		491,851		557,760

Recent Accounting Pronouncements

Commercial Services and Loan Agreements with Eversana

12 Months Ended

Dec. 31, 2022

Commercial Services And Loan Agreements [Abstract]

Commercial Services and Loan Agreements with Eversana

7. Commercial Services and Loan Agreements with Eversana

On January 21, 2020, the Company entered into a commercial services agreement (as amended, the “Eversana Agreement”) with Eversana for the commercialization of Gimoti. Pursuant to the Eversana Agreement, Eversana commercializes and

distributes Gimoti in the United States. Eversana also manages the marketing of Gimoti to targeted health care providers, as well as the sales and distribution of Gimoti in the United States.

Under the terms of the Eversana Agreement, the Company maintains ownership of the Gimoti NDA, as well as legal, regulatory, and manufacturing responsibilities for Gimoti. Eversana will utilize its internal sales organization, along with other commercial functions, for market access, marketing, distribution and other related patient support services. The Company will record sales for Gimoti and retain more than 80% of net product profits once both parties’ costs are reimbursed. For the years ended December 31, 2022 and 2021, approximately $2.0 million and $1.3 million of Eversana profit sharing costs were included as selling, general and administrative costs, respectively. As of December 31, 2022, unreimbursed commercialization costs to Eversana were approximately $48.4 million. Such costs will generally be payable only as net product profits are recognized. Eversana will receive reimbursement of its commercialization costs pursuant to an agreed upon budget and a percentage of product profits in the mid-to-high teens. Net product profits are the net sales (as defined in the Eversana Agreement) of Gimoti, less (i) reimbursed commercialization costs, (ii) manufacturing and administrative costs set at a fixed percentage of net sales, and (iii) third party royalties. During the term of the Eversana Agreement, Eversana agreed to not market, promote, or sell a competing product in the United States. On February 1, 2022, the Eversana Agreement was amended to extend the term from June 19, 2025 (five years from the date the Food & Drug Administration approved the Gimoti new drug application) to December 31, 2026, unless terminated earlier pursuant to its terms. This amendment also increased the percentage of net product profit retained by the Company and increased the proportion of costs that are reimbursed to Eversana to the extent Eversana has accumulated unreimbursed costs.

Upon expiration or termination of the agreement, the Company will retain all profits from product sales and assume all corresponding commercialization responsibilities. Within 30 days after each of the first three annual anniversaries of commercial launch, either party may terminate the agreement if net sales of Gimoti do not meet certain annual thresholds. Either party may terminate the agreement: for the material breach of the other party, subject to a 60-day cure period; in the event an insolvency, petition of the other party is pending for more than 60 days; upon 30 days written notice to the other party if Gimoti is subject to a safety recall; the other party is in breach of certain regulatory compliance representations under the agreement; if the Company discontinues the development or production of Gimoti; if the net profit is negative for any two consecutive calendar quarters beginning with the first full calendar quarter 24 months following commercial launch; if the cumulative net product profits fail to reach certain thresholds in the first three years following launch; or if there is a change in applicable laws that makes operation of the services as contemplated under the agreement illegal or commercially impractical. Either party may also terminate the Eversana Agreement upon a change of control of the Company’s ownership. In the event that the Company initiates such termination, the Company shall pay to Eversana a one-time payment equal to all of Eversana’s unreimbursed cost plus a portion of Eversana’s commercialization costs incurred in the 12 months prior to termination. Such payment amount would be reduced by the amount of previously reimbursed commercialization costs and profit split paid for the related prior twelve-month period and any revenue which occurred prior to the termination yet to be collected. If Eversana terminates the agreement due to an uncured material breach by the Company, or if the Company terminates the Eversana Agreement in certain circumstances, the Company has agreed to reimburse Eversana for its unreimbursed commercialization costs for the prior twelve-month period and certain other costs. In addition, Eversana may terminate the Eversana Agreement if the Company withdraws Gimoti from the market for more than 90 days.

In connection with the Eversana Agreement, the Company and Eversana have entered into the Eversana Credit Facility, pursuant to which Eversana has agreed to provide a revolving Credit Facility of up to $5 million to the Company upon FDA approval of the Gimoti NDA under certain customary conditions. The Eversana Credit Facility terminates on December 31, 2026, unless terminated earlier pursuant to its terms. The Eversana Credit Facility is secured by all of the Company’s personal property other than the Company’s intellectual property. Under the terms of the Eversana Credit Facility, the Company cannot grant an interest in the Company’s intellectual property to any other person. Each loan under the Eversana Credit Facility will bear interest at an annual rate equal to 10.0%, with such interest due at the end of the loan term. In 2020 the Company borrowed $5 million under the Eversana Credit Facility.

The Company may prepay any amounts borrowed under the Eversana Credit Facility at any time without penalty or premium. The maturity date of all amounts, including interest, borrowed under the Eversana Credit Facility will be 90 days after the expiration or earlier termination of the Eversana Agreement. The Eversana Credit Facility also includes events of default, the occurrence and continuation of which provide Eversana with the right to exercise remedies against the Company and the collateral securing the loans under the Eversana Credit Facility, including the Company’s cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the Eversana Credit Facility, an uncured material breach of the representations, warranties and other obligations under the Eversana Credit Facility, the occurrence of insolvency events and the occurrence of a change in control.

On November 3, 2022, the Company and Eversana entered into Amendment No. 2 (the "Amendment") to the Eversana Agreement. The Amendment provides that the preexisting rights of both parties to terminate the commercial services agreement within 30 days of the first three annual anniversaries of commercial launch, if net sales of Gimoti did not meet certain annual thresholds, would be modified solely for 2022 such that either party can terminate by written notice to the other party by November 30, 2022. Neither party terminated the Agreement under this Amendment.

Preferred Stock, Common Stock and Stockholders' Equity - Common Stock - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2017
Sale Of Common Stock [Line Items]
Common stock, shares outstanding		3,343,070	2,721,373
Shareholders voting power description		Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company.
Dividends declared on common stock		$ 0
Common stock, shares issued		3,343,070	2,721,373
Proceeds from issuance of common stock, net			$ 14,375,000
Proceeds from issuance of common stock from ATM		$ 7,443,969	$ 319,528
Public Offering [Member]
Sale Of Common Stock [Line Items]
Common stock, shares issued	479,167
Shares issued, price per share	$ 30.00
Proceeds from issuance of common stock, net	$ 14,400,000
Proceeds from issuance of common stock net of underwriting discounts and commissions and offering expenses	$ 13,100,000
FBR Sales Agreement [Member]
Sale Of Common Stock [Line Items]
Common stock, shares issued			0
FBR Sales Agreement [Member] \| Maximum [Member]
Sale Of Common Stock [Line Items]
Common stock, value of shares issuable					$ 16,000,000.0
ATM Sales Agreement [Member]
Sale Of Common Stock [Line Items]
Common stock, shares issued		621,697	18,091
Proceeds from issuance of common stock, net			$ 313,000
Common stock , weighted average price per share		$ 11.97	$ 17.66
Proceeds from issuance of common stock from ATM		$ 7,300,000
ATM Sales Agreement [Member] \| Maximum [Member]
Sale Of Common Stock [Line Items]
Available for the issuance of common stock				$ 30,000,000

Preferred Stock, Common Stock and Stockholders' Equity - Summary of Estimated Fair Value of Stock Option Award (Detail) - Common stock options [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free interest rate	1.67%	0.57%
Expected option term	5 years 6 months	5 years 6 months
Expected volatility of common stock	97.04%	103.45%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free interest rate	3.55%	1.08%
Expected option term	6 years	6 years
Expected volatility of common stock	113.23%	107.53%

Preferred Stock, Common Stock and Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail) - shares	Dec. 31, 2022	Dec. 31, 2021	Apr. 26, 2018
Share-Based Payment Arrangement [Abstract]
Stock options issued and outstanding	491,851	417,788
Authorized for future option grants	146,497	121,974
Warrants to purchase common stock	0	139,972
Authorized for employee stock purchase plan	37,048	28,715
Total common stock reserved for future issuance	675,396	708,449	323,869

Preferred Stock, Common Stock and Stockholders' Equity

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Preferred Stock, Common Stock and Stockholders' Equity

5. Preferred Stock, Common Stock and Stockholders’ Equity

Preferred Stock

Under the Company’s amended and restated certificate of incorporation, the Company is authorized to issue 5,000,000 shares of preferred stock with a $0.0001 par value. No shares of preferred stock were outstanding as of December 31, 2022 or 2021.

Common Stock

As of December 31, 2022, there were 3,343,070 shares of common stock outstanding. Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company. To date, no dividends have been declared.

Sale of Common Stock in Public Offering

In January 2021, the Company completed the sale of 479,167 shares of its common stock in an underwritten public offering led by Laidlaw & Company (UK) Ltd. The price to the public in this offering was $30.00 per share resulting in gross proceeds to the Company of approximately $14.4 million. After deducting underwriting discounts and commissions and offering expenses paid by the Company, the net proceeds to the Company raised from this offering were approximately $13.1 million.

At the Market Equity Offering Program

In November 2017, the Company filed a shelf registration with the SEC on Form S-3. The shelf registration statement included a prospectus for the at-the-market offering to sell up to an aggregate of $16.0 million of shares of the Company’s common stock through B. Riley FBR, Inc. (“FBR”) as a sales agent (the “FBR Sales Agreement”). Effective January 6, 2021, the Company terminated the FBR Sales Agreement. As a result, there were no shares sold under the FBR Sales Agreement during 2021.

In December 2020, the Company filed a new shelf registration statement with the SEC on Form S-3, or the replacement shelf registration statement. The replacement shelf registration statement replaced the registration statement on Form S-3 the Company originally filed with the SEC in November 2017, which registration statement expired in December 2020. The replacement shelf registration was declared effective by the SEC on January 6, 2021. In December 2020, the Company also entered into a new At Market Issuance Sales Agreement (the “ATM Sales Agreement”), with FBR and H.C. Wainwright & Co. (together with FBR, the “Sales Agents”), pursuant to which the Company may sell from time to time, at its option, up to an aggregate of $30 million worth of shares of the Company’s common stock through the Sales Agents. The ATM Sales Agreement provides, among other things, that sales under the ATM Sales Agreement will be made pursuant to the registration statement, including the base prospectus filed as part of such registration statement. During the year ended

December 31, 2021, the Company sold 18,091 shares of common stock at a weighted-average price per share of $17.66 pursuant to the ATM Sales Agreement and received proceeds of approximately $313,000, net of commissions and fees. During the year ended December 31, 2022, the Company sold 621,697 shares of common stock at a weighted-average price per share of $11.97 pursuant to the ATM Sales Agreement and received proceeds of approximately $7.3 million, net of commissions and fees.

Future sales under the ATM Sales Agreement will depend on a variety of factors including, but not limited to, market conditions, the trading price of the Company’s common stock and the Company’s capital needs. There can be no assurance that the Sales Agents will be successful in consummating future sales based on prevailing market conditions or in the quantities or at the prices that the Company deems appropriate.

In addition, the Company will not be able to make future sales of common stock pursuant to the ATM Sales Agreement unless certain conditions are met, which include the accuracy of representations and warranties made to the Sales Agents under the ATM Sales Agreement. Furthermore, each of the Sales Agents is permitted to terminate the ATM Sales Agreement with respect to itself in its sole discretion upon ten days’ notice, or at any time in certain circumstances, including the occurrence of an event that would be reasonably likely to have a material adverse effect on the Company’s assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders’ equity or results of operations. The Company has no obligation to sell the shares available for sale pursuant to the ATM Sales Agreement.

Warrants

The Company has issued warrants to purchase common stock to banks that have previously loaned funds to the Company, as well as to representatives of the underwriters of the Company’s public offerings and certain of their affiliates.

During 2021, there were no warrants exercised and warrants to purchase 13,517 shares of common stock expired. At December 31, 2021, there were warrants outstanding to purchase 139,972 shares of common stock with a weighted average exercise price of $34.80. During 2022, no warrants were exercised and warrants to purchase 139,972 shares of common stock expired. At December 31, 2022, there were no outstanding warrants to purchase shares of common stock.

Equity Incentive Award Plans

In August 2013, the Company adopted the 2013 Equity Incentive Award Plan (the “2013 Plan”). Under the 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company. Since its adoption, the Company’s stockholders have amended and restated the 2013 Plan. As of April 2018, the Company’s stockholders increased the number of shares of common stock authorized for issuance under the 2013 Plan to an aggregate of 323,869 shares, and extended the term of the 2013 Plan to February 2028. In addition, the number of shares available for issuance is annually increased on the first day of each fiscal year by that number of shares equal to the least of (a) four percent of the outstanding shares of common stock on the last day of the immediately preceding calendar year, and (b) such other amount determined by the Company’s board of directors. Notwithstanding the foregoing, the number of shares of common stock that may be issued or transferred pursuant to incentive stock options under the Restated Plan may not exceed an aggregate of 666,666 shares.

As a result of the annual increases since the 2013 Plan originated, and the increase of stock options reserved under the restatements of the 2013 Plan approved by the Company’s stockholders through April 2018, the Company has increased the number shares reserved for issuance under the 2013 Plan by 618,494 shares. As of December 31, 2022, 146,497 options remain available for future grant under the 2013 Plan. On January 1, 2023, the Company further increased the number of shares reserved for issuance under the 2013 Plan by 133,722 shares, making 280,219 options available for future grant under the 2013 Plan.

Options granted under the 2013 Plan have ten-year terms from the date of grant and generally vest over a one to four year period. The Company granted options to purchase 78,247 and 140,167 shares of common stock in 2022 and 2021, respectively. The exercise price of all options granted during the years ended December 31, 2022 and 2021 was equal to the market value per share of the Company’s common stock on the date of grant.

A summary of the Company’s stock option activity under the 2013 Plan is as follows:


	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding at December 31, 2021		417,788		$	21.60		7.85	—
Granted		78,247		$	6.10		9.24
Expired/Forfeited/Exchanged		(4,184	)	$	20.72		7.42
Outstanding at December 31, 2022		491,851		$	19.11		7.22	$	9,440

Vested and expected to vest at December 31, 2022		491,851		$	19.11		7.22	$	9,440

Exercisable at December 31, 2022		327,107		$	20.70		6.70	$	1,180

The aggregate intrinsic values of outstanding options is calculated as the difference between the exercise price of the underlying options and the closing price of our common stock of $2.68 at December 31, 2022.

The weighted average grant date fair value per share of employee stock options granted during the years ended December 31, 2022 and 2021, was $4.86 and $23.16, respectively.

Employee Stock Purchase Plan

In June 2013, the Company’s board of directors adopted the ESPP, and the Company’s stockholders approved the ESPP on August 29, 2013. The ESPP became effective on the day prior to the effectiveness of the IPO. The ESPP permits participants to purchase the Company’s common stock at 85% of the fair market value through payroll deductions of up to 20% of their eligible compensation. A total of 2,500 shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP has been annually increased on the first day of each fiscal year during the term of the ESPP by an amount equal to the lesser of: (i) 2,500 shares; (ii) one percent of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine.

In May 2017, the Company’s stockholders approved an amendment and restatement of the Company’s ESPP to increase the number of shares of common stock reserved under the ESPP by 8,333 shares (to an aggregate of 20,833 shares), to increase the annual evergreen provision from 2,500 shares to 8,333 shares, and to extend the term of the ESPP into 2027. The Company increased the number shares reserved for issuance under the ESPP by 60,000 shares since the inception of the ESPP. As of December 31, 2022, 37,048 shares remain available for future issuance under the ESPP. On January 1, 2023, the Company further increased the number of shares reserved for future issuance under the ESPP by 8,333 shares, making 45,381 shares available for future issuance under the ESPP after that increase.

No shares of common stock were issued through the ESPP during 2022 and 2021.

Stock-Based Compensation

Stock-based compensation expense includes charges related to employee stock purchases under the ESPP and stock option grants. The Company measures stock-based compensation expense based on the grant date fair value of any awards granted to its employees. Such expense is recognized over the period of time that employees provide service and earn rights to the awards.

The estimated fair value of each stock option award granted was determined on the date of grant using the Black Scholes option-pricing valuation model with the following assumptions for option grants during the years ended December 31, 2022 and 2021:


	Year Ended December 31,
	2022	2021
Risk free interest rate	1.67%-3.55%	0.57% - 1.08%
Expected option term	5.5- 6.0 years	5.5 - 6.0 years
Expected volatility of common stock	97.04%- 113.23%	103.45% - 107.53%
Expected dividend yield	0.0%	0.0%

The estimated fair value of the shares to be acquired under the ESPP was determined on the initiation date of each six-month purchase period using the Black-Scholes option-pricing valuation model with the following assumptions for ESPP shares to be purchased during the years ended December 31, 2022 and 2021 as follows:


	Year Ended December 31,
	2022	2021
Risk free interest rate	—	0.13%
Expected term	—	0.5 years
Expected volatility of common stock	—	111.98%
Expected dividend yield	—	0.0%

The Company recognized stock-based compensation expense to employees and directors in its research and development and its general and administrative functions during the years ended December 31, 2022 and 2021 as follows:


	Year Ended December 31,
	2022		2021
Research and development	$	11,278	$	101,754
Selling, general and administrative		1,447,431		1,777,200
Total stock-based compensation expense	$	1,458,709	$	1,878,954

As of December 31, 2022, there was approximately $1.8 million of unrecognized compensation costs related to outstanding employee and board of director options, which are expected to be recognized over a weighted-average period of 1.0 years.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consists of the following at December 31, 2022 and 2021:


	December 31,
	2022		2021
Stock options issued and outstanding		491,851		417,788
Authorized for future option grants		146,497		121,974
Warrants to purchase common stock	—			139,972
Authorized for employee stock purchase plan		37,048		28,715
Total common stock reserved for future issuance		675,396		708,449

Income Taxes - Summary of Significant Components of Deferred Tax Assets (Detail) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Acquired technology		$ 543,000
Stock compensation expense	$ 1,825,000	1,413,000
Capitalized R&D- 174	125,000
Lease liability	29,000	3,000
Accruals and other	136,000	110,000
Total deferred tax assets	2,115,000	2,069,000
Deferred tax liabilities:
Right of use asset	(29,000)	(3,000)
Total deferred tax liabilities	(29,000)	(3,000)
Less valuation allowance	$ (2,086,000)	$ (2,066,000)

Summary of Significant Accounting Policies - Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of diluted net loss per share	491,851	557,760
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of diluted net loss per share		139,972
Common stock options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of diluted net loss per share	491,851	417,788

Preferred Stock, Common Stock and Stockholders' Equity - Summary of Estimated Fair Value of Shares to be Acquired under Employee Stock Purchase Plan (Detail) - Employee stock purchase plan [Member]	12 Months Ended
	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free interest rate	0.13%
Expected term	6 months
Expected volatility of common stock	111.98%
Expected dividend yield	0.00%

Technology Acquisition Agreement

12 Months Ended

Dec. 31, 2022

Technology Acquisition Agreement [Abstract]

Technology Acquisition Agreement

4. Technology Acquisition Agreement

In June 2007, the Company acquired all worldwide rights, data, patents and other related assets associated with Gimoti from Questcor Pharmaceuticals, Inc. (“Questcor”) pursuant to an asset purchase agreement. The Company paid Questcor $650,000 in the form of an upfront payment and $500,000 in May 2014 as a milestone payment based upon the initiation of the first patient dosing in the Company’s Phase 3 clinical trial for Gimoti. In August 2014, Mallinckrodt, plc (“Mallinckrodt”) acquired Questcor. As a result of that acquisition, Questcor transferred its rights included in the asset purchase agreement with the Company to Mallinckrodt. In addition to the payments previously made to Questcor, the Company may also be required to make additional milestone payments totaling up to $52 million. In March 2018, the Company and Mallinckrodt amended the asset purchase agreement to defer development and approval milestone payments, such that, rather than paying two milestone payments based on FDA acceptance for review of the NDA and final product marketing approval, the Company would be required to make a single $5 million payment on the one-year anniversary after the Company receives FDA approval to market Gimoti. At the time of the Gimoti NDA approval, the Company recorded the $5 million payable owed to Mallinckrodt, along with a $5 million research and development expense. The $5 million milestone payment was paid in July 2021.

The remaining $47 million in milestone payments depended on Gimoti’s commercial success. The Company was required to pay Mallinckrodt a low single digit royalty percentage on net sales of Gimoti. As of December 31, 2022, the Company has paid Mallinckrodt approximately $134,000 in royalties on net sales of Gimoti. The Company’s obligation to pay such royalties and milestones terminated due to the expiration of the last patent right covering Gimoti transferred under the asset purchase agreement.

Preferred Stock, Common Stock and Stockholders' Equity - Equity Incentive Award Plans - Additional Information (Detail) - $ / shares			12 Months Ended
	Jan. 01, 2023	Apr. 26, 2018	Dec. 31, 2022	Dec. 31, 2021
Sale Of Stock [Line Items]
Aggregate number of shares of common stock reserved under the plan		323,869	675,396	708,449
Award plan expiration month and year		2028-02
Options available for future grant			146,497	121,974
Options granted, weighted average term			10 years
Number of stock options granted			78,247	140,167
Intrinsic value, common stock price			$ 2.68
Weighted Average Grant Date Fair Value Per Share, Granted			$ 4.86	$ 23.16
Minimum [Member]
Sale Of Stock [Line Items]
Options granted, vesting period			1 year
Maximum [Member]
Sale Of Stock [Line Items]
Options granted, vesting period			4 years
Amended and Restated Equity Incentive Plan 2013 [Member]
Sale Of Stock [Line Items]
Aggregate number of shares of common stock reserved under the plan		666,666
Shares available for issuance, description			In addition, the number of shares available for issuance is annually increased on the first day of each fiscal year by that number of shares equal to the least of (a) four percent of the outstanding shares of common stock on the last day of the immediately preceding calendar year, and (b) such other amount determined by the Company’s board of directors. Notwithstanding the foregoing, the number of shares of common stock that may be issued or transferred pursuant to incentive stock options under the Restated Plan may not exceed an aggregate of 666,666 shares.
Amended and Restated Equity Incentive Plan 2013 [Member] \| Annual Increase in Shares [Member]
Sale Of Stock [Line Items]
Reserve percentage for issuance of shares		4.00%
2013 Equity Incentive Award Plan [Member]
Sale Of Stock [Line Items]
Increase in the number of shares of common stock reserved under the plan				618,494
Options available for future grant			146,497
Number of stock options granted			78,247
2013 Equity Incentive Award Plan [Member] \| Subsequent Event
Sale Of Stock [Line Items]
Increase in the number of shares of common stock reserved under the plan	133,722
Options available for future grant	280,219

Preferred Stock, Common Stock and Stockholders' Equity - Employee Stock Purchase Plan and Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions		1 Months Ended		12 Months Ended
	Jan. 01, 2023	May 31, 2017	Jun. 30, 2013	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2018	Apr. 26, 2018	Apr. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation costs				$ 1.8
Weighted average period				1 year
Aggregate number of shares of common stock reserved under the plan				675,396	708,449		323,869
Shares of common stock available for future issuance under ESPP				37,048	28,715
Stock issued during period, shares, period increase						60,000
Issuance of common stock under employee stock purchase plan				0	0
Amended and Restated ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate number of shares of common stock reserved under the plan		20,833
Number of shares increased annually to common stock shares reserved for issuance		8,333						2,500
Award plan expiration year		2027
Employee stock purchase plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price of common stock as percentage of fair market value			85.00%
Percentage of deduction of eligible compensation			20.00%
Aggregate number of shares of common stock reserved under the plan			2,500
Shares available for issuance, description				In addition, the number of shares of common stock available for issuance under the ESPP has been annually increased on the first day of each fiscal year during the term of the ESPP by an amount equal to the lesser of: (i) 2,500 shares; (ii) one percent of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine.
Reserve percentage for issuance of shares			1.00%
ESPP approval date			Aug. 29, 2013
Subsequent Event \| Employee stock purchase plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate number of shares of common stock reserved under the plan	45,381
Stock issued during period, shares, period increase	8,333

Preferred Stock, Common Stock and Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Summary of Stock Option Activity

A summary of the Company’s stock option activity under the 2013 Plan is as follows:


	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding at December 31, 2021		417,788		$	21.60		7.85	—
Granted		78,247		$	6.10		9.24
Expired/Forfeited/Exchanged		(4,184	)	$	20.72		7.42
Outstanding at December 31, 2022		491,851		$	19.11		7.22	$	9,440

Vested and expected to vest at December 31, 2022		491,851		$	19.11		7.22	$	9,440

Exercisable at December 31, 2022		327,107		$	20.70		6.70	$	1,180

Summary of Estimated Fair Value of Stock Option Award


	Year Ended December 31,
	2022	2021
Risk free interest rate	1.67%-3.55%	0.57% - 1.08%
Expected option term	5.5- 6.0 years	5.5 - 6.0 years
Expected volatility of common stock	97.04%- 113.23%	103.45% - 107.53%
Expected dividend yield	0.0%	0.0%

Summary of Estimated Fair Value of Shares to be Acquired under Employee Stock Purchase Plan


	Year Ended December 31,
	2022	2021
Risk free interest rate	—	0.13%
Expected term	—	0.5 years
Expected volatility of common stock	—	111.98%
Expected dividend yield	—	0.0%

Summary of Recognized Stock-Based Compensation Expense


	Year Ended December 31,
	2022		2021
Research and development	$	11,278	$	101,754
Selling, general and administrative		1,447,431		1,777,200
Total stock-based compensation expense	$	1,458,709	$	1,878,954

Summary of Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consists of the following at December 31, 2022 and 2021:


	December 31,
	2022		2021
Stock options issued and outstanding		491,851		417,788
Authorized for future option grants		146,497		121,974
Warrants to purchase common stock	—			139,972
Authorized for employee stock purchase plan		37,048		28,715
Total common stock reserved for future issuance		675,396		708,449

Preferred Stock, Common Stock and Stockholders' Equity - Summary of Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding beginning balance	417,788
Options, Granted	78,247	140,167
Options, Outstanding ending balance	491,851	417,788
2013 Equity Incentive Award Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding beginning balance	417,788
Options, Granted	78,247
Options, Expired/Forfeited/Exchanged	(4,184)
Options, Outstanding ending balance	491,851	417,788
Options, Vested and expected to vest at December 31, 2022	491,851
Options, Exercisable at December 31, 2022	327,107
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price, Outstanding beginning balance	$ 21.60
Weighted Average Exercise Price, Granted	6.10
Weighted Average Exercise Price, Expired/Forfeited/Exchanged	20.72
Weighted Average Exercise Price, Outstanding ending balance	19.11	$ 21.60
Weighted Average Exercise Price, Vested and expected to vest at December 31, 2022	19.11
Weighted Average Exercise Price, Exercisable at December 31, 2022	$ 20.70
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]
Weighted Average Remaining Contractual Term (Years), Outstanding	7 years 2 months 19 days	7 years 10 months 6 days
Weighted Average Remaining Contractual Term (Years), Granted	9 years 2 months 26 days
Weighted Average Remaining Contractual Term (Years), Expired/Forfeited/Exchanged	7 years 5 months 1 day
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at December 31, 2022	7 years 2 months 19 days
Weighted Average Remaining Contractual Term (Years), Exercisable at December 31, 2022	6 years 8 months 12 days
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value [Abstract]
Aggregate Intrinsic Value, Outstanding ending balance	$ 9,440
Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2022	9,440
Aggregate Intrinsic Value, Exercisable at December 31, 2022	$ 1,180

Statements of Stockholders' Equity (Deficit) - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2020	$ (3,214,623)	$ 222	$ 95,670,216	$ (98,885,061)
Beginning Balance, Shares at Dec. 31, 2020		2,218,496
Stock-based compensation expense	$ 1,878,954		1,878,954
Issuance of common stock from employee stock purchase plan, shares	0
Issuance of common stock from warrant exercise, shares	0
Issuance of common stock, net of costs	$ 13,070,154	$ 48	13,070,106
Issuance of common stock, shares net		479,167
Issuance of common stock from stock option exercises	45,454		45,454
Issuance of common stock from stock option exercise, shares		5,619
Issuance of common stock from ATM offering, net of costs	313,107	$ 2	313,105
Issuance of common stock from ATM offering, net of costs, Shares		18,091
Net loss	(8,537,952)			(8,537,952)
Ending Balance at Dec. 31, 2021	$ 3,555,094	$ 272	110,977,835	(107,423,013)
Ending Balance, Shares at Dec. 31, 2021	2,721,373	2,721,373
Stock-based compensation expense	$ 1,458,709		1,458,709
Issuance of common stock from employee stock purchase plan, shares	0
Issuance of common stock from warrant exercise, shares	0
Issuance of common stock from ATM offering, net of costs	$ 7,294,976	$ 62	7,294,914
Issuance of common stock from ATM offering, net of costs, Shares		621,697
Net loss	(8,224,130)			(8,224,130)
Ending Balance at Dec. 31, 2022	$ 4,084,649	$ 334	$ 119,731,458	$ (115,647,143)
Ending Balance, Shares at Dec. 31, 2022	3,343,070	3,343,070

Preferred Stock, Common Stock and Stockholders' Equity - Summary of Recognized Stock-Based Compensation Expense (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,458,709	$ 1,878,954
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	11,278	101,754
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,447,431	$ 1,777,200

Preferred Stock, Common Stock and Stockholders' Equity - Preferred Stock - Additional Information (Detail) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares outstanding	0	0